Pharmacokinetic Profile of Myfortic in Combination With Tacrolimus in Fed Versus Fasting State

Pharmacokinetic Profile of Myfortic (Enteric Coated Mycophenolate Sodium) in a Rapid Steroid Withdrawal Protocol in Combination With Tacrolimus in Stable Renal Transplant Recipients in the Fed and Fasting State

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00585468

Enrollment

Registered

2008-01-03

Start date

2007-12-31

Completion date

2011-07-31

Last updated

2016-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Transplantation

Brief summary

Literature regarding the effect of food on the pharmacokinetic (PK) profile of enteric-coated mycophenolate sodium combined with tacrolimus and corticosteroid withdrawal is lacking. The objective of this study is to identify pharmacokinetic variables of mycophenolate sodium (Myfortic®) in the fed and fasting state in stable renal transplant patients on tacrolimus in combination with a rapid steroid withdrawal protocol.

Detailed description

Mycophenolate sodium (Myfortic®) is an antiproliferative immunosuppressant used in renal transplantation. Mycophenolate sodium is formulated as an enteric coated tablet that releases mycophenolic acid (MPA) which in turn inhibits inosine monophosphate dehydrogenase (IMPDH). Through inhibition of IMPDH, the de novo pathway of purine synthesis, which T and B lymphocytes rely on for proliferation, is blocked. The pharmacokinetic profile of mycophenolate sodium has mainly been studied in combination with cyclosporine and steroids. There is little information on the pharmacokinetics of mycophenolate sodium in combination with tacrolimus and currently no published information in steroid withdrawal. All current published data on the pharmacokinetics of MPA have been in patients receiving chronic corticosteroids as part of their immunosuppression regimen. As immunosuppression minimization, and especially corticosteroid withdrawal, become more popular it is important to understand how mycophenolate sodium and its metabolites behave in a two-drug maintenance immunosuppression regimen. The study will assess the pharmacokinetic profile of mycophenolate sodium in patients on tacrolimus dose adjusted based on levels, and a steroid withdrawal protocol. Renal transplant patients will act as their own controls in a randomized crossover design with pharmacokinetic profiles occurring at two different time points. Immunosuppression will consist of induction therapy with maintenance immunosuppression consisting of tacrolimus plus mycophenolate sodium. Corticosteroids will be withdrawn per institutional protocol within the first week post transplant. Approximately 3-4 weeks post transplant, patients that met enrollment criteria and have consented to participate in the study will be instructed to take 720 milligrams of mycophenolate sodium orally twice daily for one week either separated from food by two hours (fasting state) or with a meal (fed state). After one week, patients will be admitted for approximately 24 hours where they will continue to receive mycophenolate sodium with or without food. During this period, blood samples will be drawn at 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours following the dose to evaluate levels of mycophenolic acid (MPA) and mycophenolic acid glucuronide (MPAG). After 24 hours, patients will be discharged with instructions to take mycophenolate sodium in the opposite manner (fed or fasting state) than they had the week before. At the end of the second week the patients will return for a second PK evaluation with blood collection at the same time points following mycophenolate sodium dosing.

Interventions

DRUGMyfortic

Myfortic 720 mg orally twice daily

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Renal transplant recipients greater than 18 years of age, who have given written consent

Exclusion criteria

* Taking medications that may alter the metabolism of tacrolimus or mycophenolate sodium * Experienced an acute rejection episode prior to the pharmacokinetic profile collection * Serum creatinine \>2 mg/dL * Neutropenia (Absolute Neutrophil Count \< 1.3x10\^3/mL) * Received a previous transplant other than a kidney * Receiving chronic steroids at time of transplant * Known hypersensitivity to tacrolimus, mycophenolate mofetil, mycophenolate sodium, mycophenolic acid or any of its excipients

Design outcomes

Primary

Measure	Time frame	Description
Maximum Observed Plasma Concentration (Cmax) of Mycophenolic Acid (MPA)	0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose	—
Minimum Observed Plasma Concentration (Cmin) of Mycophenolic Acid (MPA)	0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose	—
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Mycophenolic Acid (MPA)	0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose	—
Area Under the Curve (AUC) From Time Zero to 12 Hours Post-Dose [AUC (0-12)] of Mycophenolic Acid (MPA)	0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose	AUC (0-12) = Area under the plasma concentration versus time curve from time zero (pre-dose) to 12 hours post-dose, measured in microgram-hours per milliliter (mcg\*h/mL)
Maximum Observed Plasma Concentration (Cmax) of Mycophenolic Acid Glucuronide (MPAG)	0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose	—
Minimum Observed Plasma Concentration (Cmin) of Mycophenolic Acid Glucuronide (MPAG)	0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose	—
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Mycophenolic Acid Glucuronide (MPAG)	0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose	—
Area Under the Curve From Time Zero to 12 Hours Post-Dose [AUC (0-12)] of Mycophenolic Acid Glucuronide (MPAG)	0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose	AUC (0-12) = Area under the plasma concentration versus time curve from time zero (pre-dose) to 12 hours post-dose, measured in microgram-hours per milliliter (mcg\*h/mL)

Countries

United States

Participant flow

Participants by arm

Arm	Count
Entire Study Population Includes groups randomized to the Fed State first and to the Fasted State first	21
Total	21

Withdrawals & dropouts

Period	Reason	FG000	FG001
First Intervention	Withdrawal by Subject	1	1

Baseline characteristics

Characteristic	Entire Study Population
Age, Categorical <=18 years	0 Participants
Age, Categorical >=65 years	0 Participants
Age, Categorical Between 18 and 65 years	21 Participants
Age, Continuous	43.6 years STANDARD_DEVIATION 9.8
Region of Enrollment United States	21 participants
Sex: Female, Male Female	6 Participants
Sex: Female, Male Male	15 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	— / —	— / —
other Total, other adverse events	0 / 0	0 / 0
serious Total, serious adverse events	0 / 0	0 / 0

Outcome results

Primary

Area Under the Curve (AUC) From Time Zero to 12 Hours Post-Dose [AUC (0-12)] of Mycophenolic Acid (MPA)

AUC (0-12) = Area under the plasma concentration versus time curve from time zero (pre-dose) to 12 hours post-dose, measured in microgram-hours per milliliter (mcg\*h/mL)